SHL Group will showcase its innovative devices and technologies covering different customer and patient needs in the area of autoinjectors.
Menu
Capitalizing on Taiwan’s advanced position in electronics and software development, the company also aims to set up an incubator to establish its footprint in the digital healthcare industry.
SHL will proudly showcase a range of innovative technologies and state-of-the-art designs that deliver high-quality products with an intuitive, user-friendly experience.
The annual seminar will bring together global pharma and medical device experts in an exploration of this year’s theme: the best solution for the patient from the viewpoint of drugs, containers, and devices.
Drawing over 16,000 participants from 5,000 companies last year, BIO International Convention is a premier biotech convention for industry partnering, education, and networking.
“DDP is an event that has for the past two decades been an important meeting place for drug delivery leaders.
The new global CEO for SHL Medical Holding will be Ulrich Faessler. Ulrich has been with SHL for over seven years and has been the Asian Managing Director for SHL Medical for the past five years.
The rapid growth of the biologics and biosimilars market has created a significant demand for self-injection devices for the treatment of chronic indications.
At the center of this exhibition are designs for high volume and high viscosity formulations.
